UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 8, pp. 1061 - 1075
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Recurrence | Aniline Compounds - pharmacology | Aniline Compounds - blood | Humans | Middle Aged | Blood Platelets | Male | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | fms-Like Tyrosine Kinase 3 - metabolism | fms-Like Tyrosine Kinase 3 - genetics | Retreatment | Maximum Tolerated Dose | Antineoplastic Agents - blood | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Antineoplastic Agents - pharmacology | Aniline Compounds - therapeutic use | Phosphorylation - drug effects | Pyrazines - pharmacology | Pyrazines - blood | Leukemia, Myeloid, Acute - genetics | Relapse | Diseases | Analysis | Index Medicus
Journal Article
Mayo Clinic proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 8, pp. 996 - 1000
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Drug Costs | United States - epidemiology | Neoplasms - economics | Humans | Patient Participation | Patient Advocacy | Antineoplastic Agents - economics | Neoplasms - epidemiology | Prescription Fees | Neoplasms - drug therapy | Antimitotic agents | Cancer patients | Patient outcomes | Economic aspects | Dosage and administration | Drug therapy | Antineoplastic agents | Index Medicus | Abridged Index Medicus
Journal Article
Biology of blood and marrow transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 3, pp. S202 - S202
Journal Article
Biology of blood and marrow transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 3, pp. S211 - S212
Journal Article
Biology of blood and marrow transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 2, pp. S185 - S186
Journal Article
6.
Full Text
Has there been progress in the treatment of older patients with acute myeloid leukemia?
Best practice & research. Clinical haematology, ISSN 1521-6926, 2010, Volume 23, Issue 4, pp. 495 - 501
Hematology, Oncology and Palliative Medicine | AML | elderly | karyotype | acute myeloid leukemia | clofarabine | transplantation | older | performance status | molecular | decitabine | intensive | age | azacitidine | gemtuzumab ozogamicin | Intensive | Decitabine | Clofarabine | Transplantation | Molecular | Azacitidine | Acute myeloid leukemia | Elderly | Gemtuzumab ozogamicin | Age | Karyotype | Performance status | Older | Life Sciences & Biomedicine | Hematology | Science & Technology | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Age Factors | Humans | Leukemia, Myeloid, Acute - epidemiology | Middle Aged | Survival Rate | Aged | Antineoplastic Agents - therapeutic use | Remission Induction | Leukemia, Myeloid, Acute - therapy | Aged patients | Care and treatment | Cancer | Index Medicus
Journal Article
Transfusion (Philadelphia, Pa.), ISSN 0041-1132, 02/2017, Volume 57, Issue 2, pp. 289 - 295
Life Sciences & Biomedicine | Hematology | Science & Technology | Acute Disease | Cross-Sectional Studies | United States | Humans | Middle Aged | Leukemia - therapy | Male | Blood Component Transfusion | Guideline Adherence | Adult | Female | Surveys and Questionnaires | Aged | Thrombocytopenia - therapy | Fibrin | Care and treatment | Biological products | Fibrinogen | Acute leukemia | Hemoglobin | Biological products industry | Evidence (Law) | Blood products | Leukemia | Index Medicus | transfusion threshold | blood products | transfusion | patterns of practice | acute leukemia
Journal Article
Cancer, ISSN 0008-543X, 07/2017, Volume 123, Issue 13, pp. 2472 - 2481
leukemia | leucine zipper tumor suppressor 2 (LZTS2) | nuclear receptor subfamily 6 group a member 1 (NR6A1) | methylation | survival | Life Sciences & Biomedicine | Oncology | Science & Technology | Multivariate Analysis | Prognosis | Humans | Middle Aged | Proportional Hazards Models | Male | Survival Rate | DNA Methylation - genetics | DNA-Binding Proteins - genetics | Cause of Death | Leukemia, Myeloid, Acute - mortality | Young Adult | Nuclear Receptor Subfamily 6, Group A, Member 1 - genetics | Tumor Suppressor Proteins - genetics | Adolescent | Aged, 80 and over | Cell Cycle Proteins - genetics | CpG Islands - genetics | Adult | Female | Aged | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics | Research | Nucleotide sequencing | Methylation | DNA sequencing | Bisulfite | Leukemia | Clinical trials | Shores | Genomes | Statistical methods | Leucine | Reproduction (copying) | DNA methylation | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | CpG islands | Tyrosine | Statistical analysis | Myeloid leukemia | Blood cells | Markers | Health risks | Hazards | Patients | Survival | Leucine zipper proteins | Medical prognosis | Health hazards | Cytogenetics | Tumor suppressor genes | Aberration | Acute myeloid leukemia | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Investigational new drugs, ISSN 0167-6997, 8/2013, Volume 31, Issue 4, pp. 1023 - 1034
Cytarabine | Medicine & Public Health | Oncology | Antisense | Idarubicin | Pharmacology/Toxicology | Acute myeloid leukemia | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Hematologic and hematopoietic diseases | General aspects | Pharmacology. Drug treatments | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic agents | Recurrence | Demography | Oligonucleotides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - blood | Cytarabine - therapeutic use | Idarubicin - blood | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Idarubicin - pharmacokinetics | Male | Oligonucleotides - adverse effects | Antineoplastic Agents - therapeutic use | Cytarabine - adverse effects | Oligonucleotides - pharmacokinetics | Oligonucleotides, Antisense - blood | Cytarabine - pharmacokinetics | Idarubicin - adverse effects | Antineoplastic Agents - adverse effects | Oligonucleotides, Antisense - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Female | Antineoplastic Agents - pharmacokinetics | Inhibitor of Apoptosis Proteins - metabolism | Cytarabine - blood | Idarubicin - therapeutic use | Oligonucleotides, Antisense - pharmacokinetics | Treatment Outcome | Leukemia, Myeloid, Acute - blood | Oligonucleotides, Antisense - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents - blood | Oligonucleotides - blood | Complications and side effects | Dosage and administration | Studies | Research | Drug therapy | Cancer therapies | Pharmaceutical sciences | Tumors | Index Medicus | idarubicin | cytarabine | acute myeloid leukemia | antisense
Journal Article
American journal of clinical pathology, ISSN 0002-9173, 12/2020, Volume 154, Issue 6, pp. 731 - 741
Cytogenetic analysis | Chemotherapy | Targeted agents | Diagnosis | Morphologic evaluation | Mutational analysis | Acute myeloid leukemia with myelodysplasia-related changes | CPX-351 | Life Sciences & Biomedicine | Pathology | Science & Technology | Triazines | Aminopyridines | Daunorubicin - therapeutic use | Genetic Predisposition to Disease | Prognosis | Cytarabine - therapeutic use | Leukemia, Myeloid, Acute - pathology | Humans | Antineoplastic Agents - therapeutic use | Bone Marrow Examination | PubMed | DNA Mutational Analysis | Bone Marrow - pathology | Chromosome Aberrations | Blood Cells - pathology | Leukemia, Myeloid, Acute - drug therapy | Aged | Myelodysplastic Syndromes - genetics | Cytogenetic Analysis | Myelodysplastic Syndromes - pathology | Myelodysplastic Syndromes - drug therapy | Leukemia, Myeloid, Acute - genetics | Daunorubicin | Cytarabine | Myeloid leukemia | Leukemia | Cytogenetics | Myelodysplasia | Acute myeloid leukemia | Patients | Index Medicus | Abridged Index Medicus
Journal Article
Epilepsia (Copenhagen), ISSN 0013-9580, 10/2010, Volume 51, Issue 10, pp. 1978 - 1986
Early surgery | Temporal lobe epilepsy | Randomized controlled trial | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Neurology | Pharmacology. Drug treatments | Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy | Biological and medical sciences | Anticonvulsants. Antiepileptics. Antiparkinson agents | Medical sciences | Neuropharmacology | Nervous system (semeiology, syndromes) | Double-Blind Method | Follow-Up Studies | Outcome Assessment (Health Care) | Humans | Anticonvulsants - therapeutic use | Epilepsy, Temporal Lobe - drug therapy | Male | Treatment Outcome | Epilepsy, Temporal Lobe - surgery | Positron-Emission Tomography | Electroencephalography - statistics & numerical data | Patient Selection | Epilepsy, Temporal Lobe - diagnosis | Psychiatric Status Rating Scales | Adolescent | Dominance, Cerebral | Adult | Amobarbital | Female | Neurosurgical Procedures - methods | Child | Longitudinal Studies | Research Design | Drug Resistance | Clinical trials | Neurosciences | Seizures (Medicine) | Analysis | Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 10/2014, Volume 167, Issue 1, pp. 62 - 68
prognostic models | revised international prognostic scoring system | azacitidine | myelodysplastic syndromes | French prognostic scoring system | Azacitidine | Prognostic models | Revised international prognostic scoring system | Myelodysplastic syndromes | Life Sciences & Biomedicine | Hematology | Science & Technology | Prognosis | Humans | Middle Aged | Male | Treatment Outcome | Leukemia, Myeloid, Acute - blood | Myelodysplastic Syndromes - blood | Leukemia, Myeloid, Acute - mortality | Antimetabolites, Antineoplastic - therapeutic use | Platelet Count | Myelodysplastic Syndromes - mortality | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Retrospective Studies | Myelodysplastic Syndromes - drug therapy | Azacitidine - therapeutic use | Antimitotic agents | Medical research | Patient outcomes | Medicine, Experimental | Antineoplastic agents | Index Medicus | Myelodysplastic syndromes (MDS) | French Prognostic Scoring System (FPSS) | Revised International Prognostic Scoring System (IPSS-R)
Journal Article